Clinical Trials Logo

Haematological Malignancy clinical trials

View clinical trials related to Haematological Malignancy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03146468 Active, not recruiting - Clinical trials for Haematological Malignancy

Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation

NIVALLO
Start date: May 8, 2017
Phase: Phase 2
Study type: Interventional

This is a prospective study of the safety and efficacy of nivolumab for the treatment of relapsed or residual haematological malignancies after allogeneic stem cell transplantation (alloSCT). Eligible patients will receive nivolumab at a dose of 3mg/kg intravenously every 2 weeks. The primary objective is to evaluate the incidence, severity and treatment responsiveness of GVHD following nivolumab treatment post-alloSCT.